ImmuneWorks
Pioneering safe and effective treatments for autoimmune lung diseases through groundbreaking discoveries.
Pioneering safe and effective treatments for autoimmune lung diseases through groundbreaking discoveries.
ImmuneWorks, Pioneering safe and effective treatments for autoimmune lung diseases through groundbreaking discoveries. Founded in 2006 in Indianapolis, Indiana, ImmuneWorks focuses on developing immune tolerance therapies for patients suffering from severe autoimmune lung diseases. The company's innovative approach stems from its discovery that over half of idiopathic pulmonary fibrosis (IPF) patients are affected by antigen-specific autoimmunity, guiding their mission to create safe and effective treatments for these conditions. The latest investment of $60.00K was made in a Venture Round on 26 December 2013. ImmuneWorks operates in the Biotechnology and Health Care industries. As a content writer and startup/investor analyst, ImmuneWorks' innovative approach to developing immune tolerance therapies for severe autoimmune lung diseases is noteworthy. The company's specific focus on addressing antigen-specific autoimmunity in IPF patients sets it apart in the field of biotechnology and healthcare. The $60.00K investment in a Venture Round on 26 December 2013 underscores investor confidence in ImmuneWorks' mission and potential. With its pioneering work, ImmuneWorks presents an intriguing opportunity for investors seeking to support groundbreaking advancements in autoimmune disease treatment.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Venture Round | $60.00K | - | 26 Dec 2013 | |
| Debt Financing | $375.00K | - | 17 Jul 2009 | |
| Seed Round | $300.00K | 1 |
|
30 Oct 2007 |
No recent news or press coverage available for ImmuneWorks.
We care about your data, and we'd love to use cookies make your experience better.
